Trade

with

Cerus Corp
(NASDAQ: CERS)
AdChoices
4.14
+0.02
+0.49%
After Hours :
4.14
0.00
0.00%

Open

4.11

Previous Close

4.12

Volume (Avg)

676.26k (830.53k)

Day's Range

4.02-4.16

52Wk Range

3.48-8.00

Market Cap.

306.56M

Dividend Rate ( Yield )

-

Beta

2.01

Shares Outstanding

74.05M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • -

    • Net Income

    • -

    • Market Cap.

    • 306.56M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -94.30

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.01

    • Forward P/E

    • -13.14

    • Price/Sales

    • 8.30

    • Price/Book Value

    • 6.93

    • Price/Cash flow

    • -9.71

      • EBITDA

      • -

      • Return on Capital %

      • -42.88

      • Return on Equity %

      • -68.93

      • Return on Assets %

      • -42.88

      • Book Value/Share

      • 0.60

      • Shares Outstanding

      • 74.05M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 6.75

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.52

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -15.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 19.16

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 42.95

            • 82.75

            • Pre-Tax Margin

            • -93.76

            • 39.38

            • Net Profit Margin

            • -94.30

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 41.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -82.30

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.22

              • 0.76

              • Current Ratio

              • 3.24

              • 2.92

              • Quick Ratio

              • 2.50

              • 2.35

              • Interest Coverage

              • -54.16

              • 38.02

              • Leverage Ratio

              • 1.74

              • 2.21

              • Book Value/Share

              • 0.60

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.98

                • 217.39

                • P/E Ratio 5-Year High

                • -16.72

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.28

                • 124.82

                • Price/Sales Ratio

                • 8.62

                • 9.52

                • Price/Book Value

                • 7.20

                • 8.61

                • Price/Cash Flow Ratio

                • -9.71

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -68.93

                    (-132.40)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -42.88

                    (-47.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -60.38

                    (-108.70)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 1.58

                  • 1.48

                  • Asset Turnover

                  • 0.45

                  • 0.55

                  Current Historical
                  Ownership

                  Institutional Ownership

                  57.70%

                  Top 10 Institutions

                  42.93%

                  Mutual Fund Ownership

                  22.09%

                  Float

                  87.11%

                  5% / Insider Ownership

                  2.32%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Royce Value Plus Fund

                  •  

                    2,189,500

                  • -11.70

                  • 2.96

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    2,070,940

                  • -41.58

                  • 2.80

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,174,036

                  • 0.00

                  • 1.59

                  • iShares Russell 2000 (AU)

                  •  

                    1,086,478

                  • -1.46

                  • 1.51

                  • iShares Nasdaq Biotechnology

                  •  

                    957,922

                  • -0.47

                  • 1.33

                  • Vanguard Extended Market Index Fund

                  •  

                    726,265

                  • 0.00

                  • 0.98

                  • Royce Micro Cap Series Fund

                  •  

                    699,061

                  • 0.00

                  • 0.94

                  • FCP OP MEDICAL BioHealthTrends

                  •  

                    643,045

                  • 0.00

                  • 0.85

                  • Franklin Biotechnology Discovery

                  •  

                    630,300

                  • 0.00

                  • 0.87

                  • Fidelity® Stock Selector Small Cap Fund

                  •  

                    607,138

                  • -31.25

                  • 0.82

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Baker Bros Advisors LLC

                  •  

                    10,246,591

                  • +21.19%

                  • 14.13

                  • Orbimed Advisors, LLC

                  •  

                    4,238,000

                  • 0.00%

                  • 5.84

                  • Royce & Associates, LLC

                  •  

                    3,725,505

                  • -2.14%

                  • 5.14

                  • BlackRock Fund Advisors

                  •  

                    2,664,322

                  • -5.70%

                  • 3.67

                  • Vanguard Group, Inc.

                  •  

                    2,306,310

                  • +1.96%

                  • 3.18

                  • Thomson Horstmann & Bryant, Inc.

                  •  

                    1,944,484

                  • +47.32%

                  • 2.63

                  • Cortina Asset Management LLC

                  •  

                    1,289,845

                  • +30.94%

                  • 1.78

                  • State Street Corp

                  •  

                    1,157,844

                  • -10.29%

                  • 1.60

                  • Peregrine Capital Management Inc

                  •  

                    969,689

                  • +2.94%

                  • 1.34

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT ...moreBlood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, o...morer CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 15 issued or allowed United States patents and approximately 121 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations’ blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.lessless

                  Key People

                  William M. Greenman

                  CEO/President/Director

                  Daniel N. Swisher,Jr

                  Director/Chairman of the Board

                  Dr. Laurence M. Corash,M.D.

                  Chief Medical Officer/Chief Scientific Officer/Co-Founder/Director/Senior VP

                  Kevin D. Green

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Bruce C. Cozadd

                  Director

                  • Cerus Corp

                  • 2550 Stanwell Drive

                  • Concord, CA 94520

                  • USA.Map

                  • Phone: +1 925 288-6000

                  • Fax: +1 925 288-6001

                  • cerus.com

                  Incorporated

                  1991

                  Employees

                  115

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: